W
WAVEMAN · COMPANY
EMMA · Emmaus Life Sciences, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

EMMA

Emmaus Life Sciences, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0000822370
C-SUITE BUYING · 1☆ WATCH
INSIDER NET · 180D
$15.0K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
1
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
0
13F, latest reported quarter
REVENUE GROWTH
-25.2%
XBRL, annual
NET MARGIN
-60.2%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$15.0K over 180 days
+$15.0K over 90 days
more than 68% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
fewer than five institutions report holding it
REVENUE
-25.2% year over year
below 76% of Pharma & Biotech
MARGIN
-60.2% net margin
below 59% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
<0.1% of shares outstanding short · 1.0 days to cover · settled 2026-07-31
the lowest in Pharma & Biotech
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +389.6%
+389.6%12M
-33%+166%+365%+564%2025-092025-102025-122026-032026-052026-072026-09 2026-08-28 · LEE WILLIS C bought $5.7K2026-08-31 · LEE WILLIS C bought $5.0K2026-08-27 · LEE WILLIS C bought $2.5K2026-08-25 · LEE WILLIS C bought $1.8K
INSIDER BUY
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders are net buyers of their own stock.
The record shows a net $15.0K bought by insiders over 180 days. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Emmaus Life Sciences, Inc. insiders bought a net $15.0K of stock across 206 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
LEE WILLIS C
CEO
BUY
2026-08-31
100,000.0
$5.0K
LEE WILLIS C
CEO
BUY
2026-08-28
94,767.0
$5.7K
LEE WILLIS C
CEO
BUY
2026-08-27
50,000.0
$2.5K
LEE WILLIS C
CEO
BUY
2026-08-25
46,000.0
$1.8K
LEE WILLIS C
CEO
BUY
2025-08-29
170,000.0
$1.7K
206 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 201 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$12.5M$16.7M$29.6M$18.4M
GROSS PROFIT$11.6M$15.5M$28.3M$15.8M
OPERATING INCOME$231.0K$-1.9M$3.5M$-6.6M
NET INCOME$-7.5M$-6.5M$-3.7M$-10.6M
EPS (DILUTED)-0.12-0.10-0.07-0.21
OPERATING CASH FLOW$-11.0K$-2.3M$-1.5M$-5.1M
CASH$2.1M$1.4M$2.5M$2.0M
LONG-TERM DEBT$27.1M$29.0M$30.6M$30.4M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →